BioSpace News Archive

PureTech Health plc, a clinical-stage biotherapeutics company, noted that its Founded Entity, Karuna Therapeutics, Inc. announced the submission of a New Drug Application to the U.S. Food and Drug Administration for KarXT for the treatment of schizophrenia.

Viralgen Vector Core and Elpida Therapeutics have partnered to manufacture gene therapies for use in clinical trials sponsored by Elpida Tx involving patients living with SPG50 or CMT4J.

ProQR Therapeutics NV., a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, announced that Daniel A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference in New York City.

Quris-AI, an artificial intelligence innovator disrupting the pharmaceutical arena, announced the extension of its collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company.

Integer Holdings Corporation announced that it plans to release financial and operational results for third quarter 2023, at 7 a.m. Central Time / 8 a.m. Eastern Time on Thursday, October 26, 2023.

Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine Inc. (collectively, “Clene”), today announced the publication of a scientific paper describing the catalytic mechanism of action of its investigational drug CNM-Au8® in the journal Small, a top nanotechnology-focused journal at the interface of materials science, chemistry, physics, engineering, medicine, and biology.

Cocrystal Pharma, Inc., announces dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease inhibitor CDI-988.

Vaccinex, Inc. announces a new publication in the journal mAbs describing a novel way in which its proprietary ActivMAb® poxvirus platform can enable the presentation of high complexity, hard-to-drug proteins as targets for antibody discovery.

Gradalis, Inc. announced the peer-reviewed publication in Oncology Reviews, a Frontiers Open Access Journal, highlighting Vigil activity in ovarian cancer related to clonal neoantigen expression and the HRP molecular profile.

OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, announced the appointment of Abid Ansari as Chief Financial Officer, effective immediately.